BioScrip, Inc. (NASDAQ:BIOS) (“BioScrip” or the “Company”) today
announced its fourth quarter and full-year 2016 financial results.
For the fourth quarter, the Company reported revenue from
continuing operations of $240.1 million, net loss from continuing
operations of ($5.2) million and diluted EPS of ($0.06) loss per
share. For the full-year 2016, the Company reported revenue
from continuing operations of $935.6 million, net loss from
continuing operations of ($34.4) million and diluted EPS of ($0.46)
loss per share.
Fourth Quarter Highlights
- Net revenue for the fourth quarter 2016 was $240.1 million, a
decrease of $3.6 million or 1.5% year over year, reflecting the
ongoing favorable shift in revenue mix to a greater percentage of
core revenue and less lower-margin non-core revenue;
- Core revenue increased $21.9 million or 15.1% year over year to
$166.8 million, representing core mix of 70%, up from 60% core mix
in the fourth quarter of 2015;
- We are on track to achieve the full $17.0 million in Home
Solutions synergies, and we expect to achieve an additional $23.0
to $25.0 million in cost reductions by the end of 2017. These
additional savings include workforce optimization and
reorganization, procurement and formulary management savings,
improved asset utilization, enhanced nursing productivity and
reduction of delivery costs;
- Consolidated Loss from continuing operations, net of income
taxes was $(5.2) million, an improvement of $11.8 million compared
to the prior year fourth quarter consolidated loss from continuing
operations, net of income taxes of $(17.0) million. The year over
year reduction in loss was the result of improved operating results
combined with lower restructuring costs;
- Consolidated Adjusted EBITDA was $9.5 million for the fourth
quarter 2016, as compared to the $9.0 million consolidated Adjusted
EBITDA in the prior year fourth quarter. The year over year
increase in consolidated Adjusted EBITDA was the result of improved
core mix, higher gross margins, and expense leverage in 2016.
“I am extremely pleased with the great results the
BioScrip team delivered during the quarter,” said Daniel E.
Greenleaf, President and Chief Executive Officer. “Our focus
on driving profitable growth, improving operating processes and
realizing operating cost reductions and synergies generated both
revenue and Adjusted EBITDA results for the quarter ahead of our
prior expectations. We are in the early stages of our 18 to
24 month turnaround initiative, and through ongoing work the
BioScrip team continues to uncover opportunities to drive
transformational change and unlock value throughout the
organization. BioScrip remains on pace to realize at least
$17.0 million of cumulative Home Solutions cost synergies by the
end of 2017 and we expect an incremental $23.0 million to $25.0
million in cost structure improvements during the year, a portion
of which partially offsets the negative impact of the Cures Act
legislation.”
Mr. Greenleaf added, “During the quarter our
leadership team launched the CORE initiative, a program focused on
improving Core growth, Operational efficiencies, Revenue
collections and Employee effectiveness. Continued execution
of the CORE initiative positions BioScrip for the sustainable
growth of our higher-margin core business and ongoing improvement
of our operating processes, driving our future financial
performance and creating value for our shareholders.”
Mr. Greenleaf continued, “Additionally, we are
working diligently, both internally and externally, to mitigate the
unfavorable impact of the Cures Act legislation on our business and
on the critically ill patients relying on home infusion
therapies. These efforts include actively working with
Congress and the Centers for Medicare and Medicaid Services (CMS)
to propose an amendment to the legislation to account for the
infusion benefit as well as the formation of Keep My Infusion Care
at Home, a newly established coalition of patients, family members,
caregivers, healthcare providers and related industry
organizations. For further information, please visit
http://www.keepmyinfusioncareathome.org. We have made
significant progress internally to offset the negative financial
impact of the Cures Act and through the National Home Infusion
Association (NHIA) and lobbying efforts, we remain in ongoing
discussions with the U.S. Congress on the benefits of home infusion
therapy and the impact of the Cures Act legislation.”
The Company achieved $2.6 million in Home Solutions
cost synergies in the fourth quarter of 2016. In total,
between fourth quarter 2016 realized synergies of $2.6 million and
2017 expected incremental synergies of $14.4 million, the Company
believes it is positioned to achieve the full $17.0 million in
expected Home Solutions cost synergies.
Results of Operations
Fourth Quarter 2016 versus Prior Year
Fourth Quarter 2015
Revenue from continuing operations for the fourth
quarter of 2016 was $240.1 million, compared to $243.7 million in
the fourth quarter of 2015, a decrease of $3.6 million or 1.5%.
This revenue decrease resulted from of the Company’s previously
announced shift in its revenue mix to a greater percentage of core
revenue and less lower-margin non-core revenue.
Consolidated gross profit for the fourth quarter of
2016 was $74.7 million, or 31.1% of revenue, up 410 basis points as
a percentage of revenue, compared to the prior year fourth quarter
2015 gross profit of $65.9 million, or 27.0% of revenue. The
improvement in gross profit percentage was the result of the
improved revenue mix year over year.
Consolidated Loss from continuing operations, net
of income taxes for the fourth quarter of 2016 was ($5.2) million,
representing an improvement of $11.8 million versus the same period
prior year Consolidated Loss from continuing operations, net of
income taxes of ($17.0) million. The year over year reduction
in loss was the result of improved operating results combined with
lower restructuring costs.
Consolidated Adjusted EBITDA from continuing
operations for the fourth quarter of 2016 was $9.5 million,
representing an increase of $0.5 million versus the same period
prior year Consolidated Adjusted EBITDA of $9.0 million. The
increase in Consolidated Adjusted EBITDA was the result of improved
operating results in 2016.
Full-Year 2016 versus Prior Full-Year
2015
Revenue from continuing operations for the full
year 2016 was $935.6 million, compared to $982.2 million in the
full year 2015, a decrease of $46.6 million or 4.7%. This revenue
decrease was the result of the Company’s previously announced shift
in its revenue mix to a greater percentage of core revenue and less
lower-margin non-core revenue.
Consolidated gross profit for the full year 2016
was $265.6 million, or 28.4% of revenue, up 180 basis points as a
percentage of revenue, compared to the prior full year 2015 gross
profit of $260.9 million, or 26.6% of revenue. The
improvement in gross profit percentage was the result of the
improved revenue mix year over year.
Consolidated Loss from continuing operations, net
of income taxes for the full year 2016 was ($34.4) million,
representing an improvement of $269.0 million versus the prior full
year 2015 Consolidated Loss from continuing operations, net of
income taxes of ($303.4) million. The year over year change
was the result of improved operating results in 2016 combined with
the prior year 2015 non-cash goodwill impairment charge, which did
not recur in 2016.
Consolidated Adjusted EBITDA from continuing
operations for the full year 2016 was $30.9 million, representing
an increase of $15.0 million as compared to the prior full year
2015 Consolidated Adjusted EBITDA of $15.9 million. The
increase in Consolidated Adjusted EBITDA resulted from improved
operational performance in 2016.
2017 Guidance
The Company is providing guidance for full-year
2017. This full-year 2017 guidance incorporates the estimated
negative impact of the Cures Act legislation on the Company.
The Cures Act legislation results in a significant reduction in
Medicare reimbursement rates on certain drugs effective January 1,
2017 and does not reimburse any services payments for the
administration of these drugs to patients via home infusion
pharmacies. For the full-year 2017, we are guiding to
revenues in the range of $920.0 million to $950.0 million and
adjusted EBITDA in the range of $45.0 million to $55.0 million.
Liquidity and Capital
Resources
As of yesterday, March 2, 2017, the Company had
$21.8 million of liquidity in the form of cash held in bank.
Under the terms of the Company’s Amended Credit Agreement, the
Company no longer has access to a revolving credit facility and
therefore cash held in bank represents the Company’s liquidity
position. As of December 31, 2016 the Company was in full
compliance with its bank covenants under the terms of the Amended
Credit Agreement. The Company’s net Days Sales Outstanding
(“DSO”) at December 31, 2016, was 43 days.
Conference Call and
Presentation
BioScrip will host a conference call and live
webcast, March 3, 2017, at 9:00 a.m. Eastern Time, to discuss its
fourth quarter and full year 2016 financial results. Interested
parties may participate by dialing 888-372-9592 (US) or by
accessing a link on the Company's website at
www.bioscrip.com.
A replay of the conference call will be available
for two weeks after the call's completion by dialing 855-859-2056
(US) and entering conference call ID number 5266355. An audio
webcast and archive will also be available for 30 days under the
"Investor Relations" section of the Company's website.
About BioScrip, Inc.
BioScrip, Inc. is a leading national provider of
infusion and home care management solutions. BioScrip partners with
physicians, hospital systems, skilled nursing facilities,
healthcare payors, and pharmaceutical manufacturers to provide
patients access to post-acute care services. BioScrip operates with
a commitment to bring customer-focused pharmacy and related
healthcare infusion therapy services into the home or
alternate-site setting. By collaborating with the full spectrum of
healthcare professionals and the patient, BioScrip provides
cost-effective care that is driven by clinical excellence, customer
service, and values that promote positive outcomes and an enhanced
quality of life for those it serves.
Forward-Looking Statements – Safe
Harbor
This press release includes statements that may
constitute "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995, including the
statements regarding 2017 guidance, projections of certain measures
of the Company's results of operations, projections of future
levels of certain charges and expenses, expectations of Home
Solutions cost synergies and incremental cost structure
improvements and other statements regarding the Company's financial
improvement plan and strategy. You can identify these statements by
the fact that they do not relate strictly to historical or current
facts. In some cases, forward-looking statements can be identified
by words such as "may," "should," "could," "anticipate,"
"estimate," "expect," "project," "outlook," "aim," "intend,"
"plan," "believe," "predict," "potential," "continue" or comparable
terms. Because such statements inherently involve risks and
uncertainties, actual future results may differ materially from
those expressed or implied by such forward-looking statements.
Investors are cautioned that any such forward-looking statements
are not guarantees of future performance and involve risks and
uncertainties, and that actual results may differ materially from
those in the forward-looking statements as a result of various
factors. Important factors that could cause actual results to
differ materially from those in the forward-looking statement
include but are not limited to risks associated with: the Company’s
ability to successfully integrate the HS Infusion Holdings, Inc.
business into its existing businesses; the Company's ability to
continue to execute its financial improvement plan to reduce
operating costs and focus its business on its Infusion Services
segment; the Company’s ability to evaluate opportunities for
improvement and implement solutions as part of its strategic review
process; the Company’s ability to comply with the covenants in its
debt agreements or obtain amendments to such covenants; reductions
in federal, state and commercial reimbursement for the Company's
products and services; increased government regulation related to
the health care and insurance industries; as well as the risks
described in the Company's periodic filings with the Securities and
Exchange Commission. The Company does not undertake any duty to
update these forward-looking statements after the date hereof, even
though the Company's situation may change in the future. All of the
forward-looking statements herein are qualified by these cautionary
statements.
Note Regarding Use of Non-GAAP Financial
Measures
In addition to reporting financial information in
accordance with generally accepted accounting principles (GAAP),
the Company is also reporting Adjusted EBITDA, which is a non-GAAP
financial measure. Adjusted EBITDA is not a measurement of
financial performance under GAAP and should not be used in
isolation or as a substitute or alternative to net income,
operating income or any other performance measure derived in
accordance with GAAP, or as a substitute or alternative to cash
flow from operating activities or a measure of the Company’s
liquidity. In addition, the Company's definition of Adjusted EBITDA
may not be comparable to similarly titled non-GAAP financial
measures reported by other companies. Adjusted EBITDA, as defined
by the Company, represents net income before net interest expense,
income tax expense, depreciation and amortization, impairment of
goodwill, stock-based compensation expense, and restructuring,
integration and other expenses. As part of restructuring, the
Company may incur significant charges such as the write down of
certain long−lived assets, temporary redundant expenses, retraining
expenses, potential cash bonus payments and potential accelerated
payments or terminated costs for certain of its contractual
obligations. Management believes that Adjusted EBITDA provides
useful supplemental information regarding the performance of
BioScrip’s business operations and facilitates comparisons to the
Company’s historical operating results. For a full reconciliation
of Adjusted EBITDA to the most comparable GAAP financial measure,
please see the attachment to this earnings release.
TABLES TO FOLLOW
Schedule 1 |
|
BIOSCRIP, INC. AND SUBSIDIARIES |
|
CONSOLIDATED BALANCE SHEETS |
|
(in thousands, except for share amounts) |
|
|
|
|
|
|
|
December 31, 2016 |
|
December 31, 2015 |
|
|
|
|
|
|
ASSETS |
|
|
|
|
Current
assets |
|
|
|
|
Cash and
cash equivalents |
$ |
9,569 |
|
|
$ |
15,577 |
|
|
Receivables, less allowance for doubtful accounts of $44,730 and
$59,689 |
|
|
|
|
at
December 31, 2016 and 2015, respectively |
|
111,811 |
|
|
|
97,353 |
|
|
Inventory |
|
36,165 |
|
|
|
42,983 |
|
|
Prepaid
expenses and other current assets |
|
18,507 |
|
|
|
27,772 |
|
|
Total current assets |
|
176,052 |
|
|
|
183,685 |
|
|
Property and equipment,
net |
|
32,535 |
|
|
|
31,939 |
|
|
Goodwill |
|
365,947 |
|
|
|
308,729 |
|
|
Intangible assets,
net |
|
31,043 |
|
|
|
5,128 |
|
|
Other non-current
assets |
|
2,163 |
|
|
|
1,161 |
|
|
Total assets |
$ |
607,740 |
|
|
$ |
530,642 |
|
|
LIABILITIES AND
STOCKHOLDERS' DEFICIT |
|
|
|
|
Current
liabilities |
|
|
|
|
Current
portion of long-term debt |
$ |
18,521 |
|
|
$ |
24,380 |
|
|
Accounts
payable |
|
59,134 |
|
|
|
65,077 |
|
|
Amounts
due to plan sponsors |
|
3,799 |
|
|
|
3,491 |
|
|
Accrued
interest |
|
6,705 |
|
|
|
6,898 |
|
|
Accrued
expenses and other current liabilities |
|
42,191 |
|
|
|
52,918 |
|
|
Total current liabilities |
|
130,350 |
|
|
|
152,764 |
|
|
Long-term debt, net of
current portion |
|
433,413 |
|
|
|
393,741 |
|
|
Deferred taxes |
|
2,281 |
|
|
|
236 |
|
|
Other non-current
liabilities |
|
1,257 |
|
|
|
1,861 |
|
|
Total liabilities |
|
567,301 |
|
|
|
548,602 |
|
|
|
|
|
|
|
Series A
convertible preferred stock, $.0001 par value; 825,000 shares
authorized; |
|
|
|
|
21,645
and 635,822 shares issued and outstanding; and, $2,603 and
$69,702 |
|
|
|
|
liquidation preference as of December 31, 2016 and December 31,
2015, respectively |
|
2,462 |
|
|
|
62,918 |
|
|
Series C
convertible preferred stock, $.0001 par value; 625,000 shares
authorized; |
|
|
|
|
614,177
shares issued and outstanding; and $75,491 liquidation preference
as of |
|
|
|
|
December
31, 2016 |
|
69,540 |
|
|
|
- |
|
|
Stockholders'
(deficit) equity |
|
|
|
|
Preferred stock, $.0001 par value; 5,000,000 and 4,175,000
shares authorized; no shares |
|
|
|
|
issued
and outstanding as of December 31, 2016 and December 31, 2015,
respectively |
|
- |
|
|
|
- |
|
|
Common
stock, $.0001 par value; 250,000,000 and 125,000,000 shares
authorized as of |
|
|
|
|
December
31, 2016 and December 31, 2015, respectively; 117,682,543 and
71,421,664 |
|
|
|
|
shares
issued and 117,682,543 and 68,767,613 shares outstanding as
of |
|
|
|
|
December
31, 2016 and December 31, 2015, respectively |
|
12 |
|
|
|
8 |
|
|
Treasury
stock, no shares outstanding as of December 31, 2016 and 2,654,051
shares |
|
|
|
|
outstanding, at cost, as of December 31, 2015 |
|
- |
|
|
|
(10,737 |
) |
|
Additional paid-in capital |
|
611,844 |
|
|
|
531,764 |
|
|
Accumulated deficit |
|
(643,419 |
) |
|
|
(601,913 |
) |
|
Total stockholders' deficit |
|
(31,563 |
) |
|
|
(80,878 |
) |
|
Total liabilities and stockholders' deficit |
$ |
607,740 |
|
|
$ |
530,642 |
|
|
Schedule 2 |
BIOSCRIP, INC. AND SUBSIDIARIES |
CONSOLIDATED STATEMENTS OF
OPERATIONS |
(in thousands, except per share amounts) |
|
|
|
|
|
|
|
|
Years Ended December
31, |
|
|
|
|
2016 |
|
|
|
2015 |
|
|
|
|
|
|
|
Net
revenue |
|
|
$ |
935,589 |
|
|
$ |
982,223 |
|
Cost of revenue
(excluding depreciation expense) |
|
|
|
669,958 |
|
|
|
721,308 |
|
Gross
profit |
|
|
|
265,631 |
|
|
|
260,915 |
|
% of
revenues |
|
|
|
28.4 |
% |
|
|
26.6 |
% |
|
|
|
|
|
|
Other operating
expenses |
|
|
|
170,718 |
|
|
|
165,998 |
|
Bad debt expense |
|
|
|
26,799 |
|
|
|
41,042 |
|
General and
administrative expenses |
|
|
|
39,225 |
|
|
|
42,524 |
|
Change in fair value of
equity linked liabilities |
|
|
|
(10,450 |
) |
|
|
- |
|
Impairment of
goodwill |
|
|
|
- |
|
|
|
251,850 |
|
Restructuring,
acquisition, integration, and other expenses, net |
|
|
|
15,859 |
|
|
|
24,405 |
|
Depreciation and
amortization expense |
|
|
|
21,551 |
|
|
|
22,743 |
|
Interest expense,
net |
|
|
|
38,235 |
|
|
|
37,313 |
|
(Gain) on
dispositions |
|
|
|
(3,954 |
) |
|
|
- |
|
Loss from continuing
operations, before income
taxes |
|
|
|
(32,352 |
) |
|
|
(324,960 |
) |
Income
tax expense (benefit) |
|
|
|
2,015 |
|
|
|
(21,532 |
) |
Loss from continuing operations, net of income
taxes |
|
|
|
(34,367 |
) |
|
|
(303,428 |
) |
Income
(loss) from discontinued operations, net of income taxes |
|
|
|
(7,139 |
) |
|
|
3,721 |
|
Net loss |
|
|
$ |
(41,506 |
) |
|
$ |
(299,707 |
) |
Accrued dividends on
preferred stock |
|
|
|
(8,392 |
) |
|
|
(6,120 |
) |
Deemed dividend on
preferred stock |
|
|
|
(692 |
) |
|
|
(3,690 |
) |
Loss
attributable to common stockholders |
|
|
$ |
(50,590 |
) |
|
$ |
(309,517 |
) |
|
|
|
|
|
|
Denominator - Basic and
Diluted: |
|
|
|
|
|
Weighted average
number of common shares outstanding |
|
|
|
93,740 |
|
|
|
68,710 |
|
|
|
|
|
|
|
Loss from
continuing operations, basic and diluted |
|
|
$ |
(0.46 |
) |
|
$ |
(4.56 |
) |
Income from
discontinued operations, basic and diluted |
|
|
|
(0.08 |
) |
|
|
0.05 |
|
Loss per common
share, basic and diluted |
|
|
$ |
(0.54 |
) |
|
$ |
(4.51 |
) |
|
|
|
|
|
|
Schedule 3 |
|
BIOSCRIP, INC. AND SUBSIDIARIES |
|
QUARTERLY CONSOLIDATED STATEMENTS OF
OPERATIONS |
|
(in thousands, except per share amounts) |
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
Twelve Months Ended |
|
|
|
3/31/2016 |
|
6/30/2016 |
|
9/30/2016 |
|
12/31/2016 |
|
12/31/2016 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Net
revenue |
|
$ |
238,462 |
|
|
$ |
232,462 |
|
|
$ |
224,542 |
|
|
$ |
240,123 |
|
|
$ |
935,589 |
|
|
Cost of revenue
(excluding depreciation expense) |
|
|
174,230 |
|
|
|
168,298 |
|
|
|
161,957 |
|
|
|
165,473 |
|
|
|
669,958 |
|
|
Gross
profit |
|
|
64,232 |
|
|
|
64,164 |
|
|
|
62,585 |
|
|
|
74,650 |
|
|
|
265,631 |
|
|
%
of revenues |
|
|
26.9 |
% |
|
|
27.6 |
% |
|
|
27.9 |
% |
|
|
31.1 |
% |
|
|
28.4 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
Other operating
expenses |
|
|
39,658 |
|
|
|
40,619 |
|
|
|
42,729 |
|
|
|
47,712 |
|
|
|
170,718 |
|
|
Bad debt expense |
|
|
7,592 |
|
|
|
4,279 |
|
|
|
7,727 |
|
|
|
7,201 |
|
|
|
26,799 |
|
|
General and
administrative expenses |
|
|
11,051 |
|
|
|
9,414 |
|
|
|
9,948 |
|
|
|
8,812 |
|
|
|
39,225 |
|
|
Change in fair value of
equity linked liabilities |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
(10,450 |
) |
|
|
(10,450 |
) |
|
Restructuring,
acquisition, integration, and other expenses, net |
|
|
2,667 |
|
|
|
4,291 |
|
|
|
2,368 |
|
|
|
6,533 |
|
|
|
15,859 |
|
|
Depreciation and
amortization expense |
|
|
4,538 |
|
|
|
4,252 |
|
|
|
4,166 |
|
|
|
8,595 |
|
|
|
21,551 |
|
|
Interest expense,
net |
|
|
9,412 |
|
|
|
9,469 |
|
|
|
9,331 |
|
|
|
10,023 |
|
|
|
38,235 |
|
|
(Gain) on disposition
of property and equipment |
|
|
(939 |
) |
|
|
- |
|
|
|
(3,015 |
) |
|
|
- |
|
|
|
(3,954 |
) |
|
Loss from continuing
operations, before income
taxes |
|
|
(9,747 |
) |
|
|
(8,160 |
) |
|
|
(10,669 |
) |
|
|
(3,776 |
) |
|
|
(32,352 |
) |
|
Income
tax expense |
|
|
23 |
|
|
|
149 |
|
|
|
421 |
|
|
|
1,422 |
|
|
|
2,015 |
|
|
Loss from continuing operations, net of income
taxes |
|
|
(9,770 |
) |
|
|
(8,309 |
) |
|
|
(11,090 |
) |
|
|
(5,198 |
) |
|
|
(34,367 |
) |
|
Income
(loss) from discontinued operations, net of income taxes |
|
|
233 |
|
|
|
75 |
|
|
|
(174 |
) |
|
|
(7,273 |
) |
|
|
(7,139 |
) |
|
Net loss |
|
$ |
(9,537 |
) |
|
$ |
(8,234 |
) |
|
$ |
(11,264 |
) |
|
$ |
(12,471 |
) |
|
$ |
(41,506 |
) |
|
Accrued dividends on
preferred stock |
|
|
(1,998 |
) |
|
|
(2,056 |
) |
|
|
(2,138 |
) |
|
|
(2,200 |
) |
|
|
(8,392 |
) |
|
Deemed dividends on
preferred stock |
|
|
(172 |
) |
|
|
(173 |
) |
|
|
(173 |
) |
|
|
(174 |
) |
|
|
(692 |
) |
|
Loss
attributable to common stockholders |
|
$ |
(11,707 |
) |
|
$ |
(10,463 |
) |
|
$ |
(13,575 |
) |
|
$ |
(14,845 |
) |
|
$ |
(50,590 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss per common
share: |
|
|
|
|
|
|
|
|
|
|
|
Denominator - Basic and
Diluted: |
|
|
|
|
|
|
|
|
|
|
|
Weighted average
number of common shares outstanding |
|
|
68,771 |
|
|
|
73,186 |
|
|
|
114,826 |
|
|
|
117,683 |
|
|
|
93,740 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss from
continuing operations, basic and diluted |
|
$ |
(0.17 |
) |
|
$ |
(0.14 |
) |
|
$ |
(0.12 |
) |
|
$ |
(0.06 |
) |
|
$ |
(0.46 |
) |
|
Income from
discontinued operations, basic and diluted |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
(0.06 |
) |
|
|
(0.08 |
) |
|
Net loss per
common share, basic and diluted |
|
$ |
(0.17 |
) |
|
$ |
(0.14 |
) |
|
$ |
(0.12 |
) |
|
$ |
(0.12 |
) |
|
$ |
(0.54 |
) |
|
Schedule 4 |
BIOSCRIP, INC. AND SUBSIDIARIES |
QUARTERLY CONSOLIDATED STATEMENTS OF
OPERATIONS |
(in thousands, except per share amounts) |
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
Twelve
Months Ended |
|
|
3/31/2015 |
|
6/30/2015 |
|
9/30/2015 |
|
12/31/2015 |
|
12/31/2015 |
|
|
|
|
|
|
|
|
|
|
|
Net
revenue |
|
$ |
244,357 |
|
|
$ |
246,897 |
|
|
$ |
247,224 |
|
|
$ |
243,745 |
|
|
$ |
982,223 |
|
Cost of revenue
(excluding depreciation expense) |
|
|
179,402 |
|
|
|
182,079 |
|
|
|
181,991 |
|
|
|
177,836 |
|
|
|
721,308 |
|
Gross
profit |
|
|
64,955 |
|
|
|
64,818 |
|
|
|
65,233 |
|
|
|
65,909 |
|
|
|
260,915 |
|
%
of revenues |
|
|
26.6 |
% |
|
|
26.3 |
% |
|
|
26.4 |
% |
|
|
27.0 |
% |
|
|
26.6 |
% |
|
|
|
|
|
|
|
|
|
|
|
Other operating
expenses |
|
|
41,616 |
|
|
|
43,313 |
|
|
|
41,198 |
|
|
|
39,871 |
|
|
|
165,998 |
|
Bad debt expense |
|
|
8,346 |
|
|
|
15,165 |
|
|
|
9,321 |
|
|
|
8,210 |
|
|
|
41,042 |
|
General and
administrative expenses |
|
|
11,699 |
|
|
|
11,866 |
|
|
|
9,308 |
|
|
|
9,651 |
|
|
|
42,524 |
|
Impairment of
goodwill |
|
|
- |
|
|
|
238,000 |
|
|
|
13,850 |
|
|
|
- |
|
|
|
251,850 |
|
Restructuring,
acquisition, integration, and other expenses, net |
|
|
3,704 |
|
|
|
5,969 |
|
|
|
5,369 |
|
|
|
9,363 |
|
|
|
24,405 |
|
Depreciation and
amortization expense |
|
|
5,794 |
|
|
|
6,247 |
|
|
|
5,471 |
|
|
|
5,231 |
|
|
|
22,743 |
|
Interest expense,
net |
|
|
9,163 |
|
|
|
9,080 |
|
|
|
9,507 |
|
|
|
9,563 |
|
|
|
37,313 |
|
Loss from continuing
operations, before income
taxes |
|
|
(15,367 |
) |
|
|
(264,822 |
) |
|
|
(28,791 |
) |
|
|
(15,980 |
) |
|
|
(324,960 |
) |
Income
tax expense (benefit) |
|
|
1,928 |
|
|
|
(19,921 |
) |
|
|
(4,551 |
) |
|
|
1,012 |
|
|
|
(21,532 |
) |
Loss from continuing operations, net of income
taxes |
|
|
(17,295 |
) |
|
|
(244,901 |
) |
|
|
(24,240 |
) |
|
|
(16,992 |
) |
|
|
(303,428 |
) |
(Loss)
income from discontinued operations, net of income taxes |
|
|
(2,379 |
) |
|
|
94 |
|
|
|
7,457 |
|
|
|
(1,451 |
) |
|
|
3,721 |
|
Net loss |
|
$ |
(19,674 |
) |
|
$ |
(244,807 |
) |
|
$ |
(16,783 |
) |
|
$ |
(18,443 |
) |
|
$ |
(299,707 |
) |
Accrued dividends on
preferred stock |
|
|
(453 |
) |
|
|
(1,805 |
) |
|
|
(1,899 |
) |
|
|
(1,963 |
) |
|
|
(6,120 |
) |
Deemed dividends on
preferred stock |
|
|
(1,164 |
) |
|
|
(2,186 |
) |
|
|
(169 |
) |
|
|
(171 |
) |
|
|
(3,690 |
) |
Loss
attributable to common stockholders |
|
$ |
(21,291 |
) |
|
$ |
(248,798 |
) |
|
$ |
(18,851 |
) |
|
$ |
(20,577 |
) |
|
$ |
(309,517 |
) |
|
|
|
|
|
|
|
|
|
|
|
Loss per common
share: |
|
|
|
|
|
|
|
|
|
|
Denominator - Basic and
Diluted: |
|
|
|
|
|
|
|
|
|
|
Weighted average
number of common shares outstanding |
|
|
68,637 |
|
|
|
68,698 |
|
|
|
68,742 |
|
|
|
68,760 |
|
|
|
68,710 |
|
|
|
|
|
|
|
|
|
|
|
|
Loss from
continuing operations, basic and diluted |
|
$ |
(0.28 |
) |
|
$ |
(3.62 |
) |
|
$ |
(0.38 |
) |
|
$ |
(0.28 |
) |
|
$ |
(4.56 |
) |
Income from
discontinued operations, basic and diluted |
|
|
(0.03 |
) |
|
|
- |
|
|
|
0.11 |
|
|
|
(0.02 |
) |
|
|
0.05 |
|
Net loss per
common share, basic and diluted |
|
$ |
(0.31 |
) |
|
$ |
(3.62 |
) |
|
$ |
(0.27 |
) |
|
$ |
(0.30 |
) |
|
$ |
(4.51 |
) |
Schedule 5 |
BIOSCRIP, INC. AND SUBSIDIARIES |
QUARTERLY
RECONCILIATION BETWEEN GAAP AND NON-GAAP MEASURES |
(in thousands) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
Twelve Months Ended |
|
|
3/31/2016 |
|
6/30/2016 |
|
9/30/2016 |
|
12/31/2016 |
|
12/31/2016 |
Adjusted EBITDA
by Segment: |
|
|
|
|
|
|
|
|
|
|
Infusion Services
Adjusted EBITDA |
|
$ |
16,982 |
|
|
$ |
19,266 |
|
|
$ |
12,129 |
|
|
$ |
19,737 |
|
|
$ |
68,114 |
|
Adjusted EBITDA
margin % |
|
|
7.1 |
% |
|
|
8.3 |
% |
|
|
5.4 |
% |
|
|
8.2 |
% |
|
|
7.3 |
% |
Corporate Overhead
Adjusted EBITDA |
|
|
(9,577 |
) |
|
|
(8,895 |
) |
|
|
(8,590 |
) |
|
|
(10,200 |
) |
|
|
(37,262 |
) |
Adjusted EBITDA
margin % |
|
|
(4.0 |
%) |
|
|
(3.8 |
%) |
|
|
(3.8 |
%) |
|
|
(4.2 |
%) |
|
|
(4.0 |
%) |
|
|
|
|
|
|
|
|
|
|
|
Consolidated
Adjusted EBITDA |
|
|
7,405 |
|
|
|
10,371 |
|
|
|
3,539 |
|
|
|
9,537 |
|
|
|
30,852 |
|
Adjusted EBITDA
margin % |
|
|
3.1 |
% |
|
|
4.5 |
% |
|
|
1.6 |
% |
|
|
4.0 |
% |
|
|
3.3 |
% |
|
|
|
|
|
|
|
|
|
|
|
Interest expense,
net |
|
|
(9,412 |
) |
|
|
(9,469 |
) |
|
|
(9,331 |
) |
|
|
(10,023 |
) |
|
|
(38,235 |
) |
Gain on
dispositions |
|
|
939 |
|
|
|
- |
|
|
|
3,015 |
|
|
|
- |
|
|
|
3,954 |
|
Income tax expense |
|
|
(23 |
) |
|
|
(149 |
) |
|
|
(421 |
) |
|
|
(1,422 |
) |
|
|
(2,015 |
) |
Depreciation and
amortization expense |
|
|
(4,538 |
) |
|
|
(4,252 |
) |
|
|
(4,166 |
) |
|
|
(8,595 |
) |
|
|
(21,551 |
) |
Stock-based
compensation (expense) benefit |
|
|
(1,474 |
) |
|
|
(519 |
) |
|
|
(1,358 |
) |
|
|
1,388 |
|
|
|
(1,963 |
) |
Change in fair value of
equity linked liabilities |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
10,450 |
|
|
|
10,450 |
|
Restructuring,
acquisition, integration, and other expenses, net (1) |
|
|
(2,667 |
) |
|
|
(4,291 |
) |
|
|
(2,368 |
) |
|
|
(6,533 |
) |
|
|
(15,859 |
) |
Loss from
continuing operations, net of income taxes |
|
$ |
(9,770 |
) |
|
$ |
(8,309 |
) |
|
$ |
(11,090 |
) |
|
$ |
(5,198 |
) |
|
$ |
(34,367 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
General and
Administrative Expenses on Face of Income Statement: |
|
|
|
|
|
|
|
|
|
|
Corporate overhead
adjusted EBITDA |
|
$ |
(9,577 |
) |
|
$ |
(8,895 |
) |
|
$ |
(8,590 |
) |
|
$ |
(10,200 |
) |
|
$ |
(37,262 |
) |
Stock-based
compensation (expense) |
|
|
(1,474 |
) |
|
|
(519 |
) |
|
|
(1,358 |
) |
|
|
1,388 |
|
|
|
(1,963 |
) |
General and
administrative expenses |
|
$ |
(11,051 |
) |
|
$ |
(9,414 |
) |
|
$ |
(9,948 |
) |
|
$ |
(8,812 |
) |
|
$ |
(39,225 |
) |
|
|
|
|
|
|
|
|
|
|
|
(1) Restructuring, acquisition, integration and other
expenses, net include costs associated with restructuring,
acquisition, and integration initiatives such as employee severance
costs, certain legal and professional fees, redundant wage costs,
impacts recorded from the change in contingent consideration
obligations, and other costs related to contract terminations and
closed locations. |
|
Schedule 6 |
BIOSCRIP, INC. AND SUBSIDIARIES |
QUARTERLY
RECONCILIATION BETWEEN GAAP AND NON-GAAP MEASURES |
(in thousands) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
Twelve Months Ended |
|
|
3/31/2015 |
|
6/30/2015 |
|
9/30/2015 |
|
12/31/2015 |
|
12/31/2015 |
Adjusted EBITDA
by Segment: |
|
|
|
|
|
|
|
|
|
|
Infusion Services
Adjusted EBITDA |
|
$ |
14,993 |
|
|
$ |
6,340 |
|
|
$ |
14,714 |
|
|
$ |
17,828 |
|
|
$ |
53,875 |
|
Adjusted EBITDA
margin % |
|
|
6.1 |
% |
|
|
2.6 |
% |
|
|
6.0 |
% |
|
|
7.3 |
% |
|
|
5.5 |
% |
Corporate Overhead
Adjusted EBITDA |
|
|
(10,042 |
) |
|
|
(10,704 |
) |
|
|
(8,476 |
) |
|
|
(8,789 |
) |
|
|
(38,011 |
) |
Adjusted EBITDA
margin % |
|
|
(4.1 |
%) |
|
|
(4.3 |
%) |
|
|
(3.4 |
%) |
|
|
(3.6 |
%) |
|
|
(3.9 |
%) |
|
|
|
|
|
|
|
|
|
|
|
Consolidated
Adjusted EBITDA |
|
|
4,951 |
|
|
|
(4,364 |
) |
|
|
6,238 |
|
|
|
9,039 |
|
|
|
15,864 |
|
Adjusted EBITDA
margin % |
|
|
2.0 |
% |
|
|
(1.8 |
%) |
|
|
2.5 |
% |
|
|
3.7 |
% |
|
|
1.6 |
% |
|
|
|
|
|
|
|
|
|
|
|
Interest expense,
net |
|
|
(9,163 |
) |
|
|
(9,080 |
) |
|
|
(9,507 |
) |
|
|
(9,563 |
) |
|
|
(37,313 |
) |
Income tax (expense)
benefit |
|
|
(1,928 |
) |
|
|
19,921 |
|
|
|
4,551 |
|
|
|
(1,012 |
) |
|
|
21,532 |
|
Depreciation and
amortization expense |
|
|
(5,794 |
) |
|
|
(6,247 |
) |
|
|
(5,471 |
) |
|
|
(5,231 |
) |
|
|
(22,743 |
) |
Stock-based
compensation expense |
|
|
(1,657 |
) |
|
|
(1,162 |
) |
|
|
(832 |
) |
|
|
(862 |
) |
|
|
(4,513 |
) |
Impairment of
goodwill |
|
|
- |
|
|
|
(238,000 |
) |
|
|
(13,850 |
) |
|
|
- |
|
|
|
(251,850 |
) |
Restructuring,
acquisition, integration, and other expenses, net (1) |
|
|
(3,704 |
) |
|
|
(5,969 |
) |
|
|
(5,369 |
) |
|
|
(9,363 |
) |
|
|
(24,405 |
) |
Loss from
continuing operations, net of income taxes |
|
$ |
(17,295 |
) |
|
$ |
(244,901 |
) |
|
$ |
(24,240 |
) |
|
$ |
(16,992 |
) |
|
$ |
(303,428 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
General and
Administrative Expenses on Face of Income Statement: |
|
|
|
|
|
|
|
|
|
|
Corporate overhead
adjusted EBITDA |
|
$ |
(10,042 |
) |
|
$ |
(10,704 |
) |
|
$ |
(8,476 |
) |
|
$ |
(8,789 |
) |
|
$ |
(38,011 |
) |
Stock-based
compensation expense |
|
|
(1,657 |
) |
|
|
(1,162 |
) |
|
|
(832 |
) |
|
|
(862 |
) |
|
|
(4,513 |
) |
General and
administrative expenses |
|
$ |
(11,699 |
) |
|
$ |
(11,866 |
) |
|
$ |
(9,308 |
) |
|
$ |
(9,651 |
) |
|
$ |
(42,524 |
) |
|
|
|
|
|
|
|
|
|
|
|
(1) Restructuring, acquisition, integration and other
expenses, net include costs associated with restructuring,
acquisition, and integration initiatives such as employee severance
costs, certain legal and professional fees, redundant wage costs,
impacts recorded from the change in contingent consideration
obligations, and other costs related to contract terminations and
closed locations. |
|
|
|
|
|
|
|
|
|
|
|
Schedule 7 |
|
BIOSCRIP, INC AND SUBSIDIARIES |
|
CONSOLIDATED CONDENSED CASH
FLOWS |
|
(in thousands) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
Twelve Months Ended |
|
|
3/31/2016 |
|
6/30/2016 |
|
9/30/2016 |
|
12/31/2016 |
|
12/31/2016 |
|
Cash flows from
operating activities: |
|
|
|
|
|
|
|
|
|
|
Net loss from
continuing operations |
$ |
(9,770 |
) |
|
$ |
(8,309 |
) |
|
$ |
(11,090 |
) |
|
$ |
(5,198 |
) |
|
$ |
(34,367 |
) |
|
Receivables, net of bad debt expense |
|
(4,417 |
) |
|
|
3,136 |
|
|
|
8,001 |
|
|
|
(9,222 |
) |
|
|
(2,502 |
) |
|
Inventory |
|
13,867 |
|
|
|
(3,330 |
) |
|
|
2,265 |
|
|
|
(2,786 |
) |
|
|
10,016 |
|
|
Prepaid
expenses and other assets |
|
7,897 |
|
|
|
(7,575 |
) |
|
|
8,839 |
|
|
|
(10,053 |
) |
|
|
(892 |
) |
|
Accounts
payable |
|
(11,995 |
) |
|
|
(4,195 |
) |
|
|
(15,058 |
) |
|
|
10,731 |
|
|
|
(20,517 |
) |
|
Accrued
interest |
|
(4,630 |
) |
|
|
4,438 |
|
|
|
(4,437 |
) |
|
|
4,436 |
|
|
|
(193 |
) |
|
Accrued
expenses and other liabilities |
|
(2,227 |
) |
|
|
(851 |
) |
|
|
(4,302 |
) |
|
|
(418 |
) |
|
|
(7,798 |
) |
|
Non-Cash Adjustments: |
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization |
|
4,538 |
|
|
|
4,252 |
|
|
|
4,166 |
|
|
|
8,595 |
|
|
|
21,551 |
|
|
Deferred
taxes |
|
174 |
|
|
|
178 |
|
|
|
184 |
|
|
|
1,509 |
|
|
|
2,045 |
|
|
Other
Non-Cash |
|
1,589 |
|
|
|
1,554 |
|
|
|
(5,342 |
) |
|
|
(347 |
) |
|
|
(2,546 |
) |
|
Operating Cash
Flow (Use) |
|
(4,974 |
) |
|
|
(10,702 |
) |
|
|
(16,774 |
) |
|
|
(2,753 |
) |
|
|
(35,203 |
) |
|
Discontinued operations |
|
(5,989 |
) |
|
|
76 |
|
|
|
(175 |
) |
|
|
(1,478 |
) |
|
|
(7,566 |
) |
|
Capital
expenditures |
|
(2,429 |
) |
|
|
(3,037 |
) |
|
|
(2,578 |
) |
|
|
(1,598 |
) |
|
|
(9,642 |
) |
|
Proceeds
from dispositions |
|
1,105 |
|
|
|
27 |
|
|
|
3,045 |
|
|
|
- |
|
|
|
4,177 |
|
|
Common
stock raise, net |
|
- |
|
|
|
83,267 |
|
|
|
- |
|
|
|
- |
|
|
|
83,267 |
|
|
Home
Solutions Acquisition |
|
- |
|
|
|
- |
|
|
|
(67,516 |
) |
|
|
- |
|
|
|
(67,516 |
) |
|
Term note
(repayments) |
|
(3,137 |
) |
|
|
(3,137 |
) |
|
|
(3,137 |
) |
|
|
(3,139 |
) |
|
|
(12,550 |
) |
|
Revolver
borrowing (repayments) |
|
8,000 |
|
|
|
(23,000 |
) |
|
|
39,000 |
|
|
|
16,300 |
|
|
|
40,300 |
|
|
Deferred
financing costs and other |
|
(104 |
) |
|
|
(118 |
) |
|
|
(455 |
) |
|
|
(598 |
) |
|
|
(1,275 |
) |
|
Total All Cash
Flow (Use) |
$ |
(7,528 |
) |
|
$ |
43,376 |
|
|
$ |
(48,590 |
) |
|
$ |
6,734 |
|
|
$ |
(6,008 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Schedule 8 |
|
BIOSCRIP, INC AND SUBSIDIARIES |
|
CONSOLIDATED CONDENSED CASH
FLOWS |
|
(in thousands) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
Twelve Months Ended |
|
|
3/31/2015 |
|
6/30/2015 |
|
9/30/2015 |
|
12/31/2015 |
|
12/31/2015 |
|
Cash flows from
operating activities: |
|
|
|
|
|
|
|
|
|
|
Net loss from
continuing operations |
$ |
(17,295 |
) |
|
$ |
(244,901 |
) |
|
$ |
(24,240 |
) |
|
$ |
(16,992 |
) |
|
$ |
(303,428 |
) |
|
Receivables, net of bad debt expense |
|
799 |
|
|
|
7,134 |
|
|
|
(4,310 |
) |
|
|
17,005 |
|
|
|
20,628 |
|
|
Inventory |
|
(4,666 |
) |
|
|
(483 |
) |
|
|
15,477 |
|
|
|
(16,097 |
) |
|
|
(5,769 |
) |
|
Prepaid
expenses and other assets |
|
(854 |
) |
|
|
163 |
|
|
|
(2,695 |
) |
|
|
(617 |
) |
|
|
(4,003 |
) |
|
Accounts
payable |
|
995 |
|
|
|
(13,723 |
) |
|
|
(23,094 |
) |
|
|
11,693 |
|
|
|
(24,129 |
) |
|
Accrued
interest |
|
(4,585 |
) |
|
|
4,437 |
|
|
|
(4,438 |
) |
|
|
4,630 |
|
|
|
44 |
|
|
Accrued
expenses and other liabilities |
|
(11,200 |
) |
|
|
1,267 |
|
|
|
24 |
|
|
|
1,850 |
|
|
|
(8,059 |
) |
|
Non-Cash Adjustments: |
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization |
|
5,794 |
|
|
|
6,247 |
|
|
|
5,471 |
|
|
|
5,231 |
|
|
|
22,743 |
|
|
Impairment of goodwill |
|
- |
|
|
|
238,000 |
|
|
|
13,850 |
|
|
|
- |
|
|
|
251,850 |
|
|
Deferred
Taxes |
|
1,927 |
|
|
|
(17,761 |
) |
|
|
(5,374 |
) |
|
|
1,119 |
|
|
|
(20,089 |
) |
|
Other
Non-Cash |
|
2,458 |
|
|
|
2,081 |
|
|
|
2,570 |
|
|
|
814 |
|
|
|
7,923 |
|
|
Operating Cash
Flow (Use) |
|
(26,627 |
) |
|
|
(17,539 |
) |
|
|
(26,759 |
) |
|
|
8,636 |
|
|
|
(62,289 |
) |
|
Discontinued operations |
|
(1,421 |
) |
|
|
(573 |
) |
|
|
28,669 |
|
|
|
(4,563 |
) |
|
|
22,112 |
|
|
Capital
expenditures |
|
(2,063 |
) |
|
|
(3,734 |
) |
|
|
(4,349 |
) |
|
|
(1,398 |
) |
|
|
(11,544 |
) |
|
Preferred
stock and warrants |
|
58,951 |
|
|
|
- |
|
|
|
740 |
|
|
|
- |
|
|
|
59,691 |
|
|
Revolver
borrowing (repayments) |
|
(5,000 |
) |
|
|
- |
|
|
|
30,000 |
|
|
|
(15,000 |
) |
|
|
10,000 |
|
|
Deferred
financing costs and other |
|
(1,365 |
) |
|
|
(229 |
) |
|
|
- |
|
|
|
(1,539 |
) |
|
|
(3,133 |
) |
|
Total All Cash
Flow (Use) |
$ |
22,475 |
|
|
$ |
(22,075 |
) |
|
$ |
28,301 |
|
|
$ |
(13,864 |
) |
|
$ |
14,837 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Schedule
9 |
|
|
|
|
BIOSCRIP, INC AND SUBSIDIARIES |
FULL YEAR 2017
GUIDANCE |
(dollars in millions, except EPS) |
|
|
Low
End |
|
High
End |
|
of
Range |
|
of
Range |
|
|
|
|
Revenues |
$ |
920.0 |
|
|
$ |
950.0 |
|
|
|
|
|
Adjusted
EBITDA |
|
45.0 |
|
|
|
55.0 |
|
adjusted ebitda margin |
|
4.9 |
% |
|
|
5.8 |
% |
|
|
|
|
Stock
Compensation |
|
3.0 |
|
|
|
2.5 |
|
Depreciation
& Amortization |
|
27.0 |
|
|
|
25.0 |
|
Interest Expense,
net |
|
52.0 |
|
|
|
49.0 |
|
Restructuring
Costs |
|
4.0 |
|
|
|
3.0 |
|
Income Tax
Expense |
|
3.0 |
|
|
|
2.0 |
|
Preferred Stock
Dividends |
|
9.4 |
|
|
|
9.4 |
|
Net Loss -
Continuing Ops |
$ |
(53.4 |
) |
|
$ |
(35.9 |
) |
|
|
|
|
Diluted Loss Per Common
Share |
$ |
(0.45 |
) |
|
$ |
(0.30 |
) |
|
|
|
|
weighted-average
diluted shares |
|
118,000 |
|
|
|
118,000 |
|
Investor Contacts:
Jeffrey M. Kreger
Chief Financial Officer & Treasurer
T: (720) 697-5200
jeffrey.kreger@bioscrip.com
David Clair
ICR, Inc.
T: (646) 277-1266
david.clair@icrinc.com
BioPlus Acquisition (NASDAQ:BIOS)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioPlus Acquisition (NASDAQ:BIOS)
Historical Stock Chart
From Apr 2023 to Apr 2024